Most importantly, a retrospective cohort study demonstrated that HCC tissues from patients who received a DPP4 inhibitor (sitagliptin) showed higher CD8+ T cell infiltration, while HCC tissues from patients who did not receive sitagliptin showed significantly lower CD8+ T cell infiltration [33]. This evidence concerns the gene CD8A and hepatocellular carcinoma.